Efficacy and safety of camrelizumab combined with apatinib in previously treated recurrent or metastatic nasopharyngeal carcinoma: A phase II clinical trial.

被引：0
|
作者：
Tang, Lin-Quan
Jia, Guo-Dong
Lv, Xiao-Fei
Xie, Siyi
Chen, Yu
Li, Ji-Bin
Li, Xiao Yun
Zhu, Manyi
Liu, Sai Lan
Liu, LiTing
Sun, Xue-Song
Guo, Shanshan
Luo, Dong-Hua
Chen, Qiu-Yan
Mai, Hai-Qiang
机构：
[1] Sun Yat Sen Univ, Canc Ctr, Guangzhou, Peoples R China
[2] Sun Yat Sen Univ, Guangzhou, Peoples R China
[3] Sun Yat Sen Univ, Dept Clin Res, Ctr Canc, State Key Lab Oncol South China,Collaborative Inn, Guangzhou, Peoples R China
[4] Sun Yat Sen Univ, Canc Ctr, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Guangzhou, Peoples R China
[5] Sun Yat Sen Univ, Dept Nasopharyngeal Carcinoma, Ctr Canc, Guangzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6042
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Apatinib combined with camrelizumab in the treatment of recurrent/metastatic nasopharyngeal carcinoma: a prospective multicenter phase II study
    Mo, Yunyan
    Pan, Yufei
    Zhang, Bin
    Zhang, Jian
    Su, Yixin
    Liu, Zhengchun
    Luo, Meiqing
    Qin, Guanjie
    Kong, Xiangyun
    Zhang, Rongjun
    Pan, Yu
    Liang, Yi
    Wang, Defeng
    Wei, Yuejia
    Chen, Hengwei
    Jiang, Wei
    FRONTIERS IN IMMUNOLOGY, 2024, 14
  • [2] Efficacy, safety, and biomarker analysis of Camrelizumab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma (CAPTAIN study)
    Yang, Yunpeng
    Zhou, Ting
    Chen, Xiaozhong
    Li, Jingao
    Pan, Jianji
    He, Xiaohui
    Lin, Lizhu
    Shi, Ying-rui
    Feng, Weineng
    Xiong, Jianping
    Yang, Kunyu
    Yu, Qitao
    Zhang, Qunling
    Hu, Desheng
    Sun, Yan
    Hu, Guangyuan
    Li, Ping
    Shen, Liangfang
    Lin, Qin
    Zhang, Ben
    Qu, Xiao
    Zou, Jianjun
    Zhang, Li
    Fang, Wenfeng
    Zhao, Yuanyuan
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (12)
  • [3] Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02)
    Wang, Feng-Hua
    Wei, Xiao-Li
    Feng, Jifeng
    Li, Qi
    Xu, Nong
    Hu, Xi-Chun
    Liao, Wangjun
    Jiang, Yi
    Lin, Xiao-Yan
    Zhang, Qing-yuan
    Yuan, Xiang-Lin
    Huang, Hai-Xin
    Chen, Ye
    Dai, Guang-Hai
    Shi, Jian-Hua
    Shen, Lin
    Yang, Shu-Jun
    Shu, Yong-Qian
    Liu, Yun-Peng
    Wang, Weifeng
    Wu, Hai
    Feng, Hui
    Yao, Sheng
    Xu, Rui-Hua
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (07) : 704 - +
  • [4] Efficacy and safety of camrelizumab and apatinib combined with induction chemotherapy and concurrent chemoradiotherapy for stage TanyN3M0 nasopharyngeal carcinoma: A phase II QUINTUPLED trial.
    Liang, Hu
    Wang, Lin
    Lu, Nian
    Jiang, Yao-Fei
    Wang, Jian-Wei
    Bei, Wei-Xin
    Ke, Liang-Ru
    Ye, Yan-Fang
    Liu, Guo-Ying
    Li, Wang-Zhong
    Liu, LiTing
    Duan, Jin-Ling
    Zhao, Chong
    Xia, Weixiong
    Yanqun, Xiang
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [5] Preliminary efficacy and safety of camrelizumab combined with cetuximab and chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): A phase II clinical trial.
    Ji, Dongmei
    Sang, Youzhou
    Liu, Xin
    Guo, Yanjing
    Yang, Yanan
    Chen, Guangliang
    Dong, Shu
    Wang, Yulong
    He, Xiayun
    Ying, Hongmei
    Lu, Xueguan
    Wang, Yu
    Hu, Chaosu
    Ji, Qinghai
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [6] The efficacy and safety of apatinib plus capecitabine in platinum-refractory metastatic and/or recurrent nasopharyngeal carcinoma: a prospective, phase II trial
    Tang, Lin-Quan
    Li, Xiao-Yun
    Li, Zhi-Ming
    Liu, Zhi-Gang
    Lin, Miao-Zhen
    Zhou, Huan
    Yu, Qi-Wen
    Zhou, Jian
    Zhao, Chong
    Chen, Ze-Bin
    Wang, Xi-Cheng
    Peng, Jia-Yu
    Chen, Qiu-Yan
    Fang, Wen-Feng
    Yang, Yun-Peng
    Zhang, Bei
    Xia, Liang-Ping
    Hu, Pi-Li
    Hu, Wei-Han
    Li, Yi-Jie
    Mai, Hai-Qiang
    Cai, Xiu-Yu
    BMC MEDICINE, 2023, 21 (01)
  • [7] The efficacy and safety of apatinib plus capecitabine in platinum-refractory metastatic and/or recurrent nasopharyngeal carcinoma: a prospective, phase II trial
    Lin-Quan Tang
    Xiao-Yun Li
    Zhi-Ming Li
    Zhi-Gang Liu
    Miao-Zhen Lin
    Huan Zhou
    Qi-Wen Yu
    Jian Zhou
    Chong Zhao
    Ze-Bin Chen
    Xi-Cheng Wang
    Jia-Yu Peng
    Qiu-Yan Chen
    Wen-Feng Fang
    Yun-Peng Yang
    Bei Zhang
    Liang-Ping Xia
    Pi-Li Hu
    Wei-Han Hu
    Yi-Jie Li
    Hai-Qiang Mai
    Xiu-Yu Cai
    BMC Medicine, 21
  • [8] Efficacy and safety of apatinib in recurrent/metastatic nasopharyngeal carcinoma: A pilot study
    Huang, Luo
    Zhang, Xin
    Bai, Yu
    Chua, Kevin L. M.
    Xie, Yue
    Shu, Xiaolei
    Long, Bin
    Fan, Chunbo
    Lim, Darren W. T.
    Tan, Sze Huey
    Wee, Joseph T. S.
    Wang, Ying
    Wu, Yongzhong
    Chua, Melvin L. K.
    ORAL ONCOLOGY, 2021, 115
  • [9] Efficacy and safety of cadonilimab in previously treated recurrent or metastatic nasopharyngeal carcinoma(COMPASSION-06): A phase II multicenter study
    Chen, Qiu-Yan
    Luo, Ying
    Qu, Song
    Wu, De-Hua
    Chen, Xiao-Zhong
    Chen, Don-Ping
    Qin, Xin-Tian
    Lin, Qin
    Jin, Feng
    Lin, Shao-Jun
    Yao, Zhi-Fang
    Liu, Wei
    Wang, Zhongmin Maxwell
    Li, Bai-Yong
    Xia, Michelle
    Xu, Rui-Hua
    Tang, Lin-Quan
    Mai, Hai-Qiang
    ORAL ONCOLOGY, 2024, 151
  • [10] Apatinib for locoregionally recurrent or metastatic nasopharyngeal carcinoma after failure of first-line chemotherapy: A multicenter, phase II trial.
    Jiang, Wei
    Liang, Jinghui
    Pan, Yufei
    Ruan, Xiaolan
    Cai, Rui
    He, Zhuokai
    Chen, Qiuqiu
    Zhang, Rongjun
    Yang, Xi
    Liu, Meilian
    Zhao, Bo
    Liu, Zhengchun
    Niu, Zhijie
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345